Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angina
European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
May 9th, 2008
CV Therapeutics, Inc. (NASDAQ:CVTX) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending approval of ranolazine in the European Union (EU) for the treatment of chronic angina. Following this positive recommendation from the CHMP, CV Therapeutics expects the European Commission to issue full marketing authorization for ranolazine by the end of June. The brand name for ranolazine in the product labeling is Latixa(TM). The approved indication states that ranolazine "is indicated as add-on therapy for the symptomatic treatment of patients with stable...
Source: Health Business Week (2008-05-09)
|
